ProShare Advisors LLC Acquires 18,214 Shares of Vertex Pharmaceuticals Incorporated $VRTX

ProShare Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 401,244 shares of the pharmaceutical company’s stock after purchasing an additional 18,214 shares during the period. ProShare Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $178,634,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in VRTX. Vanguard Group Inc. boosted its stake in Vertex Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 23,491,161 shares of the pharmaceutical company’s stock valued at $11,388,985,000 after acquiring an additional 232,873 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Vertex Pharmaceuticals by 21.5% in the 2nd quarter. Jennison Associates LLC now owns 6,151,505 shares of the pharmaceutical company’s stock worth $2,738,650,000 after purchasing an additional 1,089,063 shares during the period. Alliancebernstein L.P. lifted its stake in Vertex Pharmaceuticals by 0.9% in the first quarter. Alliancebernstein L.P. now owns 3,953,512 shares of the pharmaceutical company’s stock valued at $1,916,742,000 after purchasing an additional 33,492 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Vertex Pharmaceuticals by 72.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company’s stock valued at $1,414,331,000 after purchasing an additional 1,226,527 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Vertex Pharmaceuticals by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,559,476 shares of the pharmaceutical company’s stock worth $1,240,885,000 after buying an additional 230,257 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

VRTX has been the subject of several research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, October 8th. Scotiabank reduced their target price on shares of Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 5th. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their price target for the company from $458.00 to $456.00 in a research note on Thursday, September 25th. Royal Bank Of Canada reduced their price objective on shares of Vertex Pharmaceuticals from $423.00 to $415.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 4th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an “overweight” rating in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $489.10.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $409.47 on Monday. The company has a market capitalization of $103.89 billion, a PE ratio of 29.27 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The business’s fifty day moving average is $404.55 and its 200 day moving average is $429.12.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating the consensus estimate of $4.58 by $0.22. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.During the same quarter last year, the firm posted $4.38 EPS. The company’s revenue was up 11.0% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.